In This Section

Program: Friday, October 24

Wednesday, Oct. 22Thursday, Oct. 23Saturday, Oct. 25Sunday, Oct. 26

Please note that this conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. All podium presentation sessions will be recorded and made available as an on-demand program after the conference. All presentations are scheduled to be live, in-person presentations at the date and time (U.S. ET) specified in the program. Poster presentations will not be available for viewing on-demand.

Program in progress.

*-Short talk from proffered abstract

Friday, October 24

Friday, October 24

Continental Breakfast

7-8 a.m. | Ballroom Foyer and Bolyston Street Hallway

Plenary Session 3: Antibody Drug Conjugates

8-9:45 a.m. | Level 3, Ballroom AB

Session Chair: Raffaele Colombo, Zymeworks, Inc., Vancouver, BC, Canada

  • 8:05 a.m. | Dual payload ADCs: Twice the excitement, twice the complexity
    Shawn C. Owen, University of Utah, Salt Lake City, Utah
  • 8:30 a.m. | Combining ADCs with targeted therapies: Preclinical rationale for emerging clinical applications
    Bruna Pellini, H. Lee Moffitt Cancer Center, Tampa, Florida
  • 8:55 a.m. | Computational pathology in ADC biomarker development
    Mark D. Gustavson, AstraZeneca Oncology, Gaithersburg, Maryland
  • 9:20 a.m. | Phase 1 trial of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer*
    Grace K. Dy, Roswell Park Comprehensive Cancer Center, Buffalo, New York
  • 9:35 a.m. | Panel Discussion

Break

9:45-10 a.m.

Plenary Session 4: Clinical Trials Plenary Session

10-11:40 a.m. | Level 3, Ballroom AB

Session Chair: Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts

  • 10:05 a.m. | A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin: TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)*
    Samuel Klempner, Massachusetts General Hospital, Boston, Massachusetts
  • 10: 20 a.m. | Petosemtamab (MCLA-158) monotherapy or with chemotherapy in metastatic colorectal cancer: Preliminary antitumor activity and safety data from a phase 2 trial*
    Moh’d Khushman, Washington University School of Medicine, St. Louis, Missouri
  • 10:35 a.m. | Preliminary safety, pharmacokinetics, and antitumor activity of HLD-0915, a first-in-class oral RIPTAC™ binding androgen receptor (AR) and bromodomain 4 (BRD4), in patients with metastatic castrate resistant prostate cancer (mCRPC)*
    Andrew Hahn, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 10:50 a.m. | Safety and clinical activity of FX-909, a first-in-class oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), a master regulator of luminal lineage in patients with advanced urothelial carcinoma*
    Xin Gao, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
  • 11:05 a.m. | A phase I trial of the MYB RNA degrader REM-422 in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)*
    Glenn J. Hanna, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 11:20 a.m. | Rezatapopt for locally advanced or metastatic solid tumors with a TP53 Y220C mutation: Initial analysis of the pivotal PYNNACLE Phase 2 trial*
    Alison Schram, Memorial Sloan Kettering Cancer Center, New York, New York

Spotlight on Proffered Papers 2

11:45 a.m.-12:15 p.m. | Level 3, Ballroom AB

Session Chair: Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts

  • 11:45 a.m. | Efficacy and safety of ASP3082, a novel protein degrader, as monotherapy in patients (pts) with non-small cell lung cancer (NSCLC) with KRAS G12D mutation*
    Alexander Spira, Virginia Cancer Specialists and NEXT Oncology-Virginia, Fairfax, Virginia
  • 11:55 a.m. | Efficacy and safety of Elironrasib, a RAS(ON) G12C-selective inhibitor, in patients with KRAS G12C NSCLC following treatment with a KRAS(OFF) G12C inhibitor*
    Bruna Pellini, H. Lee Moffitt Cancer Center, Tampa, Florida
  • 12:05 p.m. | A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with KRASG12D mutation*
    Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

Exhibit Show

12-4 p.m. | Level 2, Exhibit Hall D

Poster Session B

12:30-4 p.m. | Level 2, Exhibit Hall D

Concurrent Sessions 4-6

4:15-5:55 p.m.

Concurrent Session 4: Cancer Vaccines

Level 3, Ballroom AB

Session Cochairs: Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York and Stephane Champiat, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 4:20 p.m. | Personalized cancer vaccines: Challenges, progress, and opportunities
    Patrick Ott, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:42 p.m. | Personalized vaccines for pancreatic cancer
    Vinod P. Balachandran
  • 5:04 p.m. | in-situ Vaccination
    Stephane Champiat
  • 5:26 p.m. | Neoadjuvant PD-1 blockade combined with therapeutic DNA vaccine and IL-7 reshapes intratumoral immunity in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC)*
    June-Young Koh, University of California San Diego, San Diego, California
  • 5:36 p.m. | Panel Discussion / Q&A

Concurrent Session 5: Emerging Targets in Development

Level 3, Rooms 302/304

Session Cochairs: Joanna Loizou, Institute of Cancer Research, London, England and Yves G. Pommier, National Cancer Institute, Bethesda, Maryland

  • 4:20 p.m. | Rational combinations with tumor-targeted anticancer agents based on pharmacokinetics and pharmacodynamic biomarkers
    Yves G. Pommier
  • 4:42 p.m. | Maximizing ATR inhibitor clinical benefit: defining novel biomarkers of response and overcoming compensatory resistance mechanisms
    Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:04 p.m. | The anion transporter GPR89 is an actionable tumour-specific dependency in breast cancer
    Joanna Loizou
  • 5:26 p.m. | Discovery of an allosteric, potent and selective DHX9 helicase inhibitor with best-in-class potential for the treatment of genomically unstable cancers*
    Taran Khanam, Storm Therapeutics, Cambridge, United Kingdom
  • 5:36 p.m. | Panel Discussion / Q&A

Concurrent Session 6: Novel Approaches in Small Molecule Development

Level 3, Ballroom C

Session Cochairs: Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, New York and Zoran Rankovic, The Institute of Cancer Research, London, United Kingdom

  • 4:20 p.m. | Mutant selective inhibitors: A clinical perspective
    Alexander Drilon
  • 4:42 p.m. | An omics approach to drug discovery
    Liron Bar-Peled, Massachusetts General Hospital, Charlestown, Massachusetts
  • 5:04 p.m. | Large-scale exploration of the cereblon neosubstrate space for targeted oncoprotein degradation
    Zoran Rankovic
  • 5:26 p.m. | RAS-mutant tumor-selective inhibition of dimeric RAF by a novel Type 1 RAF inhibitor*
    Mathieu Desaunay, Icahn School of Medicine at Mount Sinai, New York, New York
  • 5:36 p.m. | Panel Discussion / Q&A